light chain variable region cdr1 (ATCC)
ATCC is a verified supplier 
ATCC manufactures this product 
95
Structured Review
ATCC
light chain variable region cdr1
Light Chain Variable Region Cdr1, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 148 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/light+chain+variable+region+cdr1/CDR1/us12577300-18-46-80
Average 95 stars, based on 148 article reviews
Light Chain Variable Region Cdr1, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 148 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/light+chain+variable+region+cdr1/CDR1/us12577300-18-46-80
Average 95 stars, based on 148 article reviews
light chain variable region cdr1 - by Bioz Stars,
2026-10
95/100 stars
Images
Related Articles
Binding Assay:Article Title: Neutralizing antibodies to human endothelin Article Snippet: .. The present invention includes an antibody or antigen binding fragment thereof capable of specifically binding human endothelin-1, the antibody or antigen binding fragment thereof comprising a heavy chain complementarity determining region (CDR) 1, a heavy chain variable region CDR2, a heavy chain variable region CDR3, a Article Title: Neutralizing antibodies to human endothelin Article Snippet: The present invention includes an antibody or antigen binding fragment thereof capable of specifically binding human endothelin-1, the antibody or antigen binding fragment thereof comprising a heavy chain complementarity determining region (CDR) 1, a heavy chain variable region CDR2, a heavy chain variable region CDR3, a light chain variable region CDR1, a light chain variable region CDR2, and a light chain variable region CDR3 of the monoclonal antibody produced by the hybridoma cell line Nab #7 3G 9A4 deposited under ATCC[[®]] Patent Deposit Designation PTA-125818. .. The present invention includes an antibody or antigen binding fragment thereof capable of specifically binding human endothelin-1, the antibody or antigen binding fragment thereof comprising a heavy chain complementarity determining region (CDR) 1, a heavy chain variable region CDR2, a heavy chain variable region CDR3, a Article Title: Neutralizing antibodies to human endothelin Article Snippet: One embodiment includes an antibody or antigen binding fragment thereof capable of specifically binding human endothelin-1, the antibody or antigen binding fragment thereof comprising a heavy chain complementarity determining region (CDR) 1, a heavy chain variable region CDR2, a heavy chain variable region CDR3, a light chain variable region CDR1, a light chain variable region CDR2, and a light chain variable region CDR3 of the monoclonal antibody produced by the hybridoma cell line Nab #7 3G 9A4 deposited under ATCC[[®]] Patent Deposit Designation PTA-125818. .. One embodiment includes an antibody or antigen binding fragment thereof capable of specifically binding human endothelin-1, the antibody or antigen binding fragment thereof comprising a heavy chain complementarity determining region (CDR) 1, a heavy chain variable region CDR2, a heavy chain variable region CDR3, a Article Title: Neutralizing antibodies to human endothelin Article Snippet: The present invention includes an antibody or antigen binding fragment thereof capable of specifically binding human endothelin-1, the antibody or antigen binding fragment thereof comprising a heavy chain complementarity determining region (CDR) 1, a heavy chain variable region CDR2, a heavy chain variable region CDR3, a light chain variable region CDR1, a light chain variable region CDR2, and a light chain variable region CDR3 of the monoclonal antibody produced by the hybridoma cell line Nab #15 7D 489 deposited under ATCC[[®]] Patent Deposit Designation PTA-125817. .. The present invention includes an antibody or antigen binding fragment thereof capable of specifically binding human endothelin-1, the antibody or antigen binding fragment thereof comprising a heavy chain complementarity determining region (CDR) 1, a heavy chain variable region CDR2, a heavy chain variable region CDR3, a Produced:Article Title: Neutralizing antibodies to human endothelin Article Snippet: .. The present invention includes an antibody or antigen binding fragment thereof capable of specifically binding human endothelin-1, the antibody or antigen binding fragment thereof comprising a heavy chain complementarity determining region (CDR) 1, a heavy chain variable region CDR2, a heavy chain variable region CDR3, a Article Title: Neutralizing antibodies to human endothelin Article Snippet: The present invention includes an antibody or antigen binding fragment thereof capable of specifically binding human endothelin-1, the antibody or antigen binding fragment thereof comprising a heavy chain complementarity determining region (CDR) 1, a heavy chain variable region CDR2, a heavy chain variable region CDR3, a light chain variable region CDR1, a light chain variable region CDR2, and a light chain variable region CDR3 of the monoclonal antibody produced by the hybridoma cell line Nab #7 3G 9A4 deposited under ATCC[[®]] Patent Deposit Designation PTA-125818. .. The present invention includes an antibody or antigen binding fragment thereof capable of specifically binding human endothelin-1, the antibody or antigen binding fragment thereof comprising a heavy chain complementarity determining region (CDR) 1, a heavy chain variable region CDR2, a heavy chain variable region CDR3, a Article Title: Neutralizing antibodies to human endothelin Article Snippet: One embodiment includes an antibody or antigen binding fragment thereof capable of specifically binding human endothelin-1, the antibody or antigen binding fragment thereof comprising a heavy chain complementarity determining region (CDR) 1, a heavy chain variable region CDR2, a heavy chain variable region CDR3, a light chain variable region CDR1, a light chain variable region CDR2, and a light chain variable region CDR3 of the monoclonal antibody produced by the hybridoma cell line Nab #7 3G 9A4 deposited under ATCC[[®]] Patent Deposit Designation PTA-125818. .. One embodiment includes an antibody or antigen binding fragment thereof capable of specifically binding human endothelin-1, the antibody or antigen binding fragment thereof comprising a heavy chain complementarity determining region (CDR) 1, a heavy chain variable region CDR2, a heavy chain variable region CDR3, a Article Title: Neutralizing antibodies to human endothelin Article Snippet: The present invention includes an antibody or antigen binding fragment thereof capable of specifically binding human endothelin-1, the antibody or antigen binding fragment thereof comprising a heavy chain complementarity determining region (CDR) 1, a heavy chain variable region CDR2, a heavy chain variable region CDR3, a light chain variable region CDR1, a light chain variable region CDR2, and a light chain variable region CDR3 of the monoclonal antibody produced by the hybridoma cell line Nab #15 7D 489 deposited under ATCC[[®]] Patent Deposit Designation PTA-125817. .. The present invention includes an antibody or antigen binding fragment thereof capable of specifically binding human endothelin-1, the antibody or antigen binding fragment thereof comprising a heavy chain complementarity determining region (CDR) 1, a heavy chain variable region CDR2, a heavy chain variable region CDR3, a other:Article Title: Neutralizing antibodies to human endothelin Article Snippet: One embodiment includes an antibody or antigen binding fragment thereof capable of specifically binding human endothelin-1, the antibody or antigen binding fragment thereof comprising the heavy chain variable region (VH) and light chain variable region (VL) of the monoclonal antibody produced by the hybridoma cell line Nab #15 Article Title: Neutralizing antibodies to human endothelin Article Snippet: One embodiment includes an antibody or antigen binding fragment thereof capable of specifically binding human endothelin-1, the antibody or antigen binding fragment thereof comprising the heavy chain variable region (VH) and light chain variable region (VL) of the monoclonal antibody produced by the hybridoma cell line Nab #7 |